What question did this study set out to answer?

To evaluate the long-term outcomes associated with cribriform status in prostate cancer after radical prostatectomy.

March 30, 2026Open Access

Long‐term outcomes of cribriform‐positive and cribriform‐negative prostate cancer treated with radical prostatectomy in the ProtecT trial

Key Points

To evaluate the long-term outcomes associated with cribriform status in prostate cancer after radical prostatectomy.
Analysis of the ProtecT trial data
Assessment of cribriform status as a binary outcome
Follow-up over a 15-year period
Identified risk of metastasis or death based on cribriform status
Higher risk in cribriform-positive, high-grade and/or pT3b tumours
Highlights need for targeted adjuvant therapy for specific populations

Abstract

In the ProtecT trial, the 15-year risk of metastasis or death after RP was a binary outcome defined by cribriform status. The concentration of risk in men with cribriform-positive, high-grade and/or pT3b tumours identifies a target population for adjuvant therapy trials, while supporting management de-escalation for most RP patients.

Long‐term outcomes of cribriform‐positive and cribriform‐negative prostate cancer treated with radical prostatectomy in the ProtecT trial

Key Points

Abstract

Cite This Study